129.09 0.00 (0.00%)
After hours: 5:31PM EST
|Bid||124.24 x 1100|
|Ask||132.55 x 800|
|Day's Range||126.35 - 130.26|
|52 Week Range||61.96 - 260.98|
|Beta (3Y Monthly)||0.41|
|PE Ratio (TTM)||33.03|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||3.00 (2.30%)|
|1y Target Est||226.67|
NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Herbalife Nutrition (NYSE:HLF) has won its long-running battle with the shorts. Herbalife stock is up 60% since the beginning of 2018, touching an all-time high earlier this month. And most shorts have moved on in the process: less than 10% of HLF stock is sold short at the moment, down from levels that were consistently above 25% as recently as 2017.Source: Shutterstock But Herbalife stock is pulling back slightly in trading on Wednesday. HLF is down 2.6% as of this writing after its fourth-quarter earnings report on Tuesday afternoon. The pullback makes some sense. * 7 Healthy Dividend Stocks to Buy for Extra Stability HLF has put many of its risks behind it. It continues to grow earnings. But 2019 guidance isn't quite as good as investors were hoping for -- and with the stock not far off its highs, more was priced in.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Herbalife EarningsQ4 earnings from Herbalife appear relatively in line with overall expectations. Adjusted earnings per share of 63 cents did decline 3% year over year, but the figure came in 2 cents above analyst expectations. Revenue growth of 9% matched the Street consensus, though an early January update from Herbalife had pointed analysts in the right direction.So, there wasn't much in the way of surprise -- and likely little to change the minds of either bulls or bears. HLF bulls can point to strong performance in both Q4 and for the full year, over which time sales rose 10%. A 30% rise in "volume points" in Asia Pacific during the fourth quarter shows continued improvement in that key Herbalife market.With regulatory pressure in the U.S. seemingly behind the company, that growth is what matters to Herbalife stock. And the company is delivering.The one piece of somewhat disappointing news came in terms of 2019 guidance. Herbalife projects EPS of $2.90-$3.10 for 2019. That's below analyst consensus of $3.20. Currency headwinds may be a factor, however: HLF is guiding for a 22-cent impact on this year's earnings from the stronger dollar. Including that impact, the midpoint of adjusted EPS guidance suggests less than 1% growth. Backing out those external effects, however, Herbalife earnings (on a non-GAAP basis) should rise more than 8% year over year. The HLF Stock Battleground Remains IntactAgain, Q4 results and 2019 guidance likely do little to change the mind of investors on either side of the HLF trade. Bulls see continued growth on both the top and bottom line. The smaller, but still-vocal, bearish contingent will point out, as Josh Enomoto did, that the company still is a multi-level marketer (MLM).Yes, Herbalife settled with U.S. regulators. But foreign entities may have different standards -- a potential risk as Herbalife increasingly focuses as international growth. The stronger dollar makes the potential profit for that risk even smaller, at least for U.S. shareholders.Even the sudden departure of the company's then-CEO last month can be viewed in different ways. It turned out that Richard Goudis was caught on tape telling an employee in Asia to ignore expense-account limits on entertainment. To bears, this was a sign that the company's culture, even at the top, was based on skirting the rules.Yet, Herbalife stock actually touched its all-time high a few weeks after Goudis' departure, likely in part because traders thought the exit opened up the possibility of a go-private deal. Here, too, both sides viewed the news through their own respective lens. Herbalife Stock Isn't CheapFrom here, the HLF battleground looks likely to result in a stalemate after the Q4 report. Bears aren't going anywhere. Neither are bulls. And the valuation assigned to Herbalife stock looks about right -- if not a touch high.The midpoint of 2019 EPS guidance suggests an 18.8 P/E multiple for HLF. That's a multiple that assumes some growth -- and about what Herbalife is projecting it will post in 2019. From that standpoint, HLF looks reasonably valued.But there are risks underlying the story here -- even if bears have overestimated those risks in the past. Note that other MLMs like Nu Skin Enterprises (NYSE:NUS) and Medifast (NYSE:MED) have taken big hits in recent months. (Medifast admittedly had soared before pulling back by roughly 50%; that stock still is up 89% over the past year.)In that context, unless HLF's growth expectations rise over the course of the year, it's tough to see Herbalife stock clearing $60 again. 20 times $3 per share in earnings looks like a potential ceiling -- and suggests just 6.7% returns from this level. * 7 Restaurant Stocks to Watch in 2019 And it's worth remembering that for the first half of the decade, HLF was a volatile stock -- but one that traded mostly sideways. Right now, I'd expect that type of trading to return in 2019 (although, perhaps, in a tighter range given the lower short interest). Q4 results were good, and Herbalife is going to grow. But that's already priced in. For the next few quarters at least, the movement in HLF is going to come down to whether the company can beat guidance -- and whether the bulls can hold off the bears.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Cheap Stocks to Buy Right Now * 5 Stocks Under $5 to Buy Before They Soar * 5 Consumer Stocks to Cash Out Of Compare Brokers The post Earnings Signify the End of the Rally in Herbalife Stock appeared first on InvestorPlace.
BALTIMORE, Feb. 12, 2019 /PRNewswire/ -- Medifast, Inc. (MED), a leading manufacturer and distributor of clinically proven, healthy living products and programs, will announce financial results for the fourth quarter and full year ended December 31, 2018 on Tuesday, February 26, 2019, after market close. The Company will host a conference call to discuss these results with additional comments and details. Participants from the Company will be Dan Chard, Chief Executive Officer, and Tim Robinson, Chief Financial Officer.
Here are two stocks moving higher on news and two others showing weakening technical indicators. American Superconductor (AMSC) jumped 66 cents to $14.54 Thursday on 604,100 shares traded, or double the average volume.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends can be underrated but they form Read More...
Companies would not be allowed to buy back their own shares unless they pay employees $15 per hour, provide paid sick leave, and offer pensions and better health benefits under a plan proposed by U.S. Sens. Chuck Schumer and Bernie Sanders.
Medifast (NYSE:MED) is a relative newcomer to the weight loss and weight management industry, having started in 1980. Both Weight Watchers International (NASDAQ:WTW) and Nutrisystem (NASDAQ:NTRI) started a decade or two before MED. The one thing MED stock had that made it unique, however, is that it was started by a doctor and was originally sold through doctors and doctors' offices. And while obesity wasn't the issue it is today, there were plenty of reasons to get Americans on healthier diets, like high blood pressure, fast food and prepared foods, lack of exercise, etc. InvestorPlace - Stock Market News, Stock Advice & Trading Tips This also lent an air of credibility, since it was basically doctors "prescribing" you food. Since then, the company has grown steadily … until recently when it began to go on a tear. ### Big Growth for MED Stock In the past three years, MED stock is up more than 320%. In the past 12 months, it's up 85%. And its current price-to-earnings ratio is still below 33. That's pretty impressive. That means it's significantly outperforming its competitors in the space. WTW and NTRI are both treading water, or slightly under for the past 12 months. What's more, since it wasn't originally built for speed, MED stock offers a respectable 2.4% dividend as well. * 7 S&P 500 Stocks to Buy That Tore Up Earnings All these stocks are considered specialty retail, since they are focused on the consumer. This sector is doing well, it's just that WTW and NTRI were the default choices in the sector and were overbought. Also, being the market leaders, they were the ones that were most exposed to competitors who could take market share. But as long as the consumer is doing well, these firms will do well. The second important factor is, younger generations aren't necessarily as much food oriented as they are nutrition oriented. What I mean by that is, they don't see food as an indulgence necessarily. They care where their food is sourced and that what they eat gives them what they need, just as long as it's easy to eat and fast to prepare. This culture has been developing over time as prepared foods have become much higher quality and more thoughtful, and consumers have spent less time in kitchens learning how to cook. This trend also works for the graying baby boomers who are less interested in cooking and may have chronic illnesses -- diabetes, heart disease, etc -- where having prepared meals makes sense. Chef Mike (the microwave) is now our private chef. MED's fastest growing division is its Optavia unit. It is marketed solely by word of mouth and uses one-on-one coaches who are current or former Medifast customers. The help keep their clients on their targets and help them build menus and meal plans that are customized. The consultants are paid a commission for their sales, so this also becomes a great supplemental income source for MED's best customers. This is a unique time to sneak in here as well, since the big names in the sector aren't performing well, so this is an under-the-radar play at the moment in a sector that has huge long-term potential. Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post Thereas Still Plenty of Upside Left in Medifast Stock appeared first on InvestorPlace.
Today we'll look at Medifast, Inc. (NYSE:MED) and reflect on its potential as an investment. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an Read More...
BALTIMORE , Jan. 8, 2019 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of clinically proven, healthy living products and programs, announced today that Dan Chard , ...
WW, formerly known as Weight Watchers International Inc. , is one of the health and beauty companies in the D.A. Davidson coverage universe that's "recession resistant," analysts wrote in a Thursday note. Analysts used eight criteria to determine recession resistance including sales decline in the last recession and operating leverage. WW has "low operating leverage, high operating and free cash flow margins, and strong strategic position," D.A. Davidson said. Still, shares are down 46.6% over the past three months. Medifast Inc. , a company that provides weight-loss plans, sits atop this list thanks to its "debt-free balance sheet, high free cash flow margin, and lack of sales cyclicality." Medifast shares are down 45% for the last three months. In comparison, the S&P 500 index has slumped 16% for the past three months. D.A. Davidson rates both WW and Medifast shares at buy. It has a $137 price target on WW, and a $249 price target on Medifast.
Herbalife stock has benefited from an earnings turnaround and sales acceleration. Investors flocked to health and wellness companies this year.
The 10 speciality retail stocks to buy below are great examples of this. Many of the featured companies are designed for the price-conscious consumer that is looking for a good deal but also wants something that isn’t cheap.
If you are interested in cashing in on Medifast, Inc.'s (NYSE:MED) upcoming dividend of US$0.75 per share, you only have 3 days left to buy the shares before its ex-dividend Read More...
The quarterly cash dividend of $0.75 per share is payable on February 7, 2019 to stockholders of record as of the close of business on December 21, 2018. "This increase reflects our confidence in the business as well our commitment to deliver attractive total stockholder returns," said Dan Chard, Chief Executive Officer of Medifast.
Medifast Inc (NYSE:MED) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case Read More...
BALTIMORE, Nov. 14, 2018 /PRNewswire/ -- Medifast, Inc. (MED), a leading manufacturer and distributor of clinically proven, healthy living products and programs, today announced it has completed a $10 million stock repurchase. This repurchase was made as part of the Company's existing stock repurchase program that was previously approved by its Board of Directors. "Our stock repurchase demonstrates the confidence our Board of Directors and executive team has in Medifast's long-term growth trajectory and the strength of our balance sheet and cash flow," said Tim Robinson, Chief Financial Officer of Medifast.
The sharp drop comes as Medifast's stock has been one of the biggest movers of the year, rising more than three-fold since January to an all-time high of $248.98 on Sept. 10.
Medifast (MED) delivered earnings and revenue surprises of -0.87% and 11.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Baltimore-based company said it had net income of $1.14. The weight-loss company posted revenue of $139.2 million in the period. For the current quarter ending in December, Medifast ...
Third Quarter Revenue Increased 80% and EPS Increased 107% Record Financial Results Exceed Third Quarter Guidance Raises Fiscal Year 2018 Outlook BALTIMORE , Nov. 6, 2018 /PRNewswire/ -- Medifast, Inc. ...